FDA Brief

Warning letters Drugs

FDA warning letter to

Kardesler Ucan Yaglar Sanayi Anonim Sirketi

High riskIssued Jan 21, 2025Posted Jan 28, 2025Center for Drug Evaluation and Research (CDER)

Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.

What happened

FDA did not inspect; it reviewed records the firm sent after FDA's March 15, 2024 request for records under section 704(a)(4) of the FD&C Act, a provision that lets FDA demand records instead of visiting. The records did not show that the firm tested each lot of glycerin and propylene glycol for diethylene glycol (DEG) and ethylene glycol (EG), or its ethanol for methanol, and did not show finished-product testing for identity and strength of active ingredients such as ethanol and benzalkonium chloride. FDA also found the quality unit did not properly approve or reject components.

What FDA found

  1. The firm did not run at least one identity test on each incoming lot of components, including glycerin, propylene glycol and ethanol.

    21 CFR 211.84(d)(1)
  2. The firm did not test each batch of finished drug product for identity and strength of active ingredients before releasing it.

    21 CFR 211.165(a)
  3. The firm's quality unit did not have or use the authority to approve or reject components and other materials.

    21 CFR 211.22(a)

What FDA wants

FDA tells the firm to correct the violations promptly and to reply in writing within 15 working days saying what it has done and how it will prevent recurrence; if fixes cannot be finished in that time, it must give reasons and a schedule. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • US brands and distributors buying OTC hand sanitizing wipes or other drugs from this firm
  • suppliers and buyers of glycerin, propylene glycol and ethanol for drug use
  • companies that rely on a supplier's certificate instead of their own identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk